Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.64 |
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.55 |
| ▸ | REN | P00797 | 2/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619803 | 0.97 | C5AR1 (0.65) | C5AR1APLNRAGTR2AGTR1EPHA2 | |
| SCHEMBL29976469 | 0.97 | C5AR1 (0.65) | C5AR1APLNRAGTR2AGTR1EPHA2 | |
| SCHEMBL29701260 | 0.96 | C5AR1 (0.60) | C5AR1APLNRAGTR2AGTR1 | |
| SCHEMBL9010599 | 0.95 | AGTR1 (0.62) | C5AR1APLNRAGTR2AGTR1REN | |
| SCHEMBL29649735 | 0.95 | AGTR1 (0.62) | C5AR1APLNRAGTR2AGTR1REN | |
| SCHEMBL9010604 | 0.95 | AGTR1 (0.62) | C5AR1APLNRAGTR2AGTR1REN | |
| [Val5] - Angiotensin Ii SCHEMBL29551599 | 0.94 | AGTR2 (0.64) | C5AR1APLNRAGTR2AGTR1EPHA2 | |
| SCHEMBL29551271 | 0.94 | C5AR1 (0.62) | C5AR1APLNRAGTR2AGTR1EPHA2 | |
| Angiotensin Amide SCHEMBL29619836 | 0.94 | C5AR1 (0.62) | C5AR1APLNRAGTR2AGTR1EPHA2 | |
| Acetic Acid SCHEMBL29619795 | 0.94 | AGTR1 (0.61) | C5AR1APLNRAGTR2AGTR1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | C5AR1 939/4885APLNR 208/4885AGTR2 337/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | C5AR1 939/4885APLNR 208/4885AGTR2 337/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | C5AR1 3824/4885APLNR 1505/4885AGTR2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.